References
- 1. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. European Journal of Endocrinology 2014; 4 1-29. DOI: 10.1530/EJE-14-025310.1530/EJE-14-025324849517
- 2. Wang R, Mol BW. The Rotterdam criteria for polycystic ovary syndrome: evidence-based criteria? Hum Reprod. 2017 Feb; 32(2):261-4. DOI: 10.1093/humrep/dew28710.1093/humrep/dew28728119448
- 3. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the Polycystic Ovary Syndrome. Int J Obes Relat Metab Disord. 2002 Jul;26(7):883-96. DOI: 10.1038/sj.ijo.080199410.1038/sj.ijo.080199412080440
- 4. Sha, T, Wang X, Cheng W, Yan Y. A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF. Reprod Biomed Online. 2019 Aug;39(2):281-93. DOI: 10.1016/j.rbmo.2019.03.20310.1016/j.rbmo.2019.03.20331255606
- 5. De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F. Genetic, hormonal and metabolic aspects of PCOS: an update. Reprod Biol Endocrinol. 2016 Jul 16;14(1):38. DOI: 10.1186/s12958-016-0173-x10.1186/s12958-016-0173-x494729827423183
- 6. Haoula Z, Ravipati S, Stekel DJ, Ortori CA, Hodgman C, Daykin C et al. Lipidomic analysis of plasma samples from women with polycystic ovary syndrome Metabolomics. 2015;11(3):657-66. DOI: 10.1007/s11306-014-0726-y10.1007/s11306-014-0726-y441915525972770
- 7. Dong F, Deng D, Chen H, Cheng W, Li Q, Luo R et al. Serum metabolomics study of polycystic ovary syndrome based on UPLC-QTOF-MS coupled with a pattern recognition approach. Anal Bioanal Chem. 2015 Jun;407(16):4683-95 DOI: 10.1007/s00216-015-8670-x10.1007/s00216-015-8670-x25860656
- 8. Vonica CL, Fodor A, Roman G, Mureasan AA, Farcas AD, Inceu GV, et al. Metabolic Analysis in Women with Polycystic Ovary Highlight Specific Biomarkers of Insulin Resistance. Rev.Chim.(Bucharest). 2019;70(10):3644-8 DOI: 10.37358/RC.19.10.761310.37358/RC.19.10.7613
- 9. Bellver J, De Los Santos MJ, Alamá P, Castelló D, Privitera L, Galliano D et al. Day-3 embryo metabolomics in the spent culture media is altered in obese women undergoing in vitro fertilization. Fertil Steril. 2015 Jun;103(6):1407-15.e1 DOI: 10.1016/j.fertnstert.2015.03.01510.1016/j.fertnstert.2015.03.01525935493
- 10. Vonica CL, Ilie IR, Socaciu C, Moraru C, Georgescu B, Farcaş A et al. Lipidomics biomarkers in women with polycystic ovary syndrome (PCOS) using ultra-high performance liquid chromatography-quadrupole time of flight electrospray in a positive ionization mode mass spectrometry. Scand J Clin Lab Invest. 2019 Oct;79(6):437-42. DOI: 10.1080/00365513.2019.165821510.1080/00365513.2019.165821531462125
- 11. Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016 Jul;17(7):451-9. DOI: 10.1038/nrm.2016.2510.1038/nrm.2016.25572991226979502
- 12. Kosmides AK, Kamisoglu K, Calvano SE, Corbett SA, Androulakis IP. Metabolomic Fingerprinting: Challenges and Opportunities. Crit Rev Biomed Eng. 2013;41(3):205-21. DOI: 10.1615/CritRevBiomedEng.201300773610.1615/CritRevBiomedEng.2013007736
- 13. Zhou B, Feng Xiao J, Tuli L. LC-MS-based metabolomics. Mol Biosyst. 2012 Feb; 8(2): 470-81. DOI: 10.1039/C1MB05350G10.1039/C1MB05350G
- 14. Lee K-M, Jeon J-Y, Lee B-J, Lee H, Choi H-K. Application of Metabolomics to Quality Control of Natural Product Derived Medicines. Biomol Ther (Seoul). 2017;25(6):559-68. DOI: 10.4062/biomolther.2016.24910.4062/biomolther.2016.249568542428605829
- 15. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-12. DOI: 10.1016/j.jclinepi.2009.06.00510.1016/j.jclinepi.2009.06.00519631508
- 16. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73: 712-6. DOI: 10.1046/j.1445-2197.2003.02748.x10.1046/j.1445-2197.2003.02748.x12956787
- 17. Higgins JPT SJ, Savović J, Page MJ, Hróbjartsson A, Boutron I, Reeves B, Eldridge S. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, Welch V, editors. Cochrane Methods. Cochrane Database of Systematic Reviews 2016, Issue 10 (Suppl 1).
- 18. National Heart, Lung and blood institute. Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies https://www.Int J Diabetes Dev Ctries Author’s personal copy nhlbi.nih.gov/health-topics/study-quality-assessment-tools. Accessed 28 Mar 2019.
- 19. Escobar-Morreale HF, Samino S, Insenser M, Vinaixa M, Luque-Ramírez M, Lasunción MA et al. Metabolic heterogeneity in polycystic ovary 846 syndrome is determined by obesity: plasma metabolomic approach using GC- 847 MS. Clin. Chem. 2012; 58, 999-1009. DOI: 10.1373/clinchem.2011.17639610.1373/clinchem.2011.17639622427353
- 20. Troisi J, Cinque C, Giugliano L, Symes S, Richards S, Adair D. Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study. J Ovarian Res. 2019 Mar 23;12(1):25. DOI: 10.1186/s13048-019-0500-x10.1186/s13048-019-0500-x643102530904021
- 21. Goodpaster BH, Wolfe RR, Kelley DE. Effects of obesity on substrate utilization during exercise. Obesit Res. 2002;10(7):575-84. DOI: 10.1038/oby.2002.7810.1038/oby.2002.7812105277
- 22. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: A reexamination. Diabetes. 2000; 49(5):677-83. DOI: 10.2337/diabetes.49.5.67710.2337/diabetes.49.5.67710905472
- 23. Di Sarra D, Tosi F, Bonin C, Fiers T, Kaufman JM, Signori C et al. Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism. J Clin Endocrinol Metabol. 2013;98(6):2581-8. DOI: 10.1210/jc.2013-116110.1210/jc.2013-1161
- 24. Whigham LD, Butz DE, Dashti H, Tonelli M, Johnson LK, Cook ME et al. Metabolic Evidence of Diminished Lipid Oxidation in Women With Polycystic Ovary Syndrome. Curr Metabolomics. 2014;2(4):269-78. DOI: 10.2174/2213235X0166613120323051210.2174/2213235X01666131203230512
- 25. Zhao X, Xu F, Qi B, Hao S, Li Y, Li Y et al. Serum Metabolomics Study of Polycystic Ovary Syndrome Based on Liquid Chromatography−Mass Spectrometry. J. Proteome Res. 2014;13(2):1101-11 DOI: 10.1021/pr401130w10.1021/pr401130w
- 26. Sun L, Hu W, Liu Q, Hao Q, Sun B, Zhang Q et al. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Ovarian Res. 2019 Mar 23;12(1):25.
- 27. Zhao H, Zhao Y, Li T, Li M, Li J, Li R et al. Metabolism alteration in follicular niche: the nexus between intermediary metabolism, mitochondrial function, and classic polycystic ovary syndrome. Free Radic Biol Med. 2015 Sep;86:295-307. DOI: 10.1016/j.freeradbiomed.2015.05.01310.1016/j.freeradbiomed.2015.05.013
- 28. Attie AD, Krauss RM, Gray-Keller MP, Brownlie A, Miyazaki M, Kastelein JJ et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J. Lipid Res. 2002, 43 (11), 1899−1907. DOI: 10.1194/jlr.M200189-JLR20010.1194/jlr.M200189-JLR200
- 29. Ntambi JM. The regulation of stearoyl-CoA desaturase (SCD). Prog. Lipid Res. 1995, 34 (2), 139−150. DOI: 10.1016/0163-7827(94)00010-J10.1016/0163-7827(94)00010-J
- 30. Dobrzyn, A, Ntambi JM. The role of stearoyl-CoA desaturase in body weight regulation. Trends Cardiovasc. Med. 2004, 14 (2), 77− 81. DOI: 10.1016/j. tcm.2003.12.00510.1016/j.tcm.2003.12.005
- 31. Brown JM, Chung, S, Sawyer JK, Degirolamo C, Alger HM, Nguyen TM et al. Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 inhibition prevents the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010 Jan;30(1):24-30. DOI: 10.1161/ATVBAHA.109.19803610.1161/ATVBAHA.109.198036279629319834103
- 32. Mar-Heyming R, Miyazaki M, Weissglas-Volkov D, Kolaitis NA, Sadaat N, Plaisier C et al. Association of stearoyl-CoA desaturase 1 activity with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1193-9. DOI: 10.1161/ATVBAHA.107.16015010.1161/ATVBAHA.107.160150275876818340007
- 33. Perez-Chacon G, Astudillo AM, Ruiperez V, Balboa MA, Balsinde J. Signaling role for lysophosphatidylcholine acyltransferase 3 in receptor-regulated arachidonic acid reacylation reactions in human monocytes. J. Immunol. 2010; 184 (2), 1071−8. DOI: 10.4049/jimmunol.090225710.4049/jimmunol.090225720018618
- 34. Barber MN, Risis S, Yang C, Meikle PJ, Staples M, Febbraio MA et al. Plasma Lysophosphatidylcholine Levels Are Reduced in Obesity and Type 2 Diabetes. PLoS One. 2012;7(7):e41456. DOI: 10.1371/journal. pone.004145610.1371/journal.pone.0041456
- 35. Chang AY, Lalia AZ, Jenkins GD, Dutta T, Carter RE, Singh RJ et al. Combining a Nontargeted and Targeted Metabolomics Approach to Identify Metabolic Pathways Significantly Altered in Polycystic Ovary Syndrome. Metabolism. 2017 Jun;71:52-63. DOI: 10.1016/j.metabol.2017.03.00210.1016/j.metabol.2017.03.002552053928521878
- 36. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012 Dec; 33(6):981-1030. DOI: 10.1210/er.2011-103410.1210/er.2011-1034539315523065822
- 37. Wang W, Wang S, Tan S, Wen M, Qian Y, Zeng X et al. Detection of urine metabolites in polycystic ovary syndrome by UPLC triple-TOF-MS. Clin Chim Acta. 2015 Aug 25;448:39-47. DOI: 10.1016/j.cca.2015.06.00810.1016/j.cca.2015.06.00826093338
- 38. Zhao Y, Fu L, Li R, Wang LN, Yang Y, Liu NN et al. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Medicine. 2012 Nov 30;10:153. DOI: 10.1186/1741-7015-10-15310.1186/1741-7015-10-153359923323198915
- 39. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011 Apr;17(4):448-53. Epub 2011 Mar 20. DOI: 10.1038/nm.230710.1038/nm.2307312661621423183
- 40. Martin FP, Montoliu I, Collino S, Scherer M, Guy P, Tavazzi I, et al. Topographical body fat distribution links to amino acid and lipid metabolism in healthy non-obese women. LoS One. 2013 Sep 11;8(9):e73445. DOI: 10.1371/journal.pone.007344510.1371/journal.pone.0073445377064024039943
- 41. Chand AL, Legge M. 2011. Amino acid transport system L activity in developing mouse ovarian follicles. Hum Reprod. 2011 Nov;26(11):3102-8. DOI: 10.1093/humrep/der29810.1093/humrep/der29821914669
- 42. She P, Olson KC, Kadota Y, Inukai A, Shimomura Y, Hoppel CL, et al Leucine and protein metabolism in obese Zucker rats, PLoS One. 2013;8(3):e59443.. DOI: 10.1371/journal.pone.005944310.1371/journal.pone.0059443360388323527196
- 43. Li X, Wang Y, Tang W, Liu C, Chen Y, Zheng Z. Relationship between ADIPOQ polymorphisms and polycystic ovary syndrome: a meta-analysis involving 6,735 subjects. Int J Clin Exp Med 2017;10(2):1828-39.
- 44. Halama A, Aye MM, Dargham SR., Kulinski M, Suhre K, Atkin SL. Metabolomics of Dynamic Changes in Insulin Resistance Before and After Exercise in PCOS. Front Endocrinol (Lausanne). 2019 Feb 27;10:116. DOI: 10.3389/fendo.2019.0011610.3389/fendo.2019.00116640083430873121
- 45. Rodríguez-Gallego E, Guirro M, Riera-Borrull M, Hernández-Aguilera A, Mariné-Casadó R, Fernández-Arroyo S, et al. Mapping of the circulating metabolome reveals α-ketoglutarate as a predictor of morbid obesity-associated non-alcoholic fatty liver disease. Int J Obes (Lond). 2015 Feb;39(2):279-87. DOI: 10.1038/ijo.2014.5310.1038/ijo.2014.5324675715
- 46. Gaster M, Nehlin JO, Minet AD. Impaired TCA cycle flux in mitochondria in skeletal muscle from type 2 diabetic subjects: marker or maker of the diabetic pheno-type? Arch Physiol Biochem. 2012 Jul;118(3):156-89. DOI: 10.3109/13813455.2012.65665310.3109/13813455.2012.65665322385297
- 47. Jimenez PT, Frolova AI, Chi MM, Grindler NM, Will-cockson AR, Reynolds KA, et al. DHEA-mediated inhibition of the pentose phosphate pathway alters oocyte lipid metabolism in mice. Endocrinology. 2013 Dec;154(12):4835-44. DOI: 10.1210/en.2012-214010.1210/en.2012-2140383606524036000
- 48. Guan HP, Goldstein JL, Brown MS, Liang G. Accelerated fatty acid oxidation in muscle averts fasting-induced hepatic steatosis in SJL/J mice. J Biol Chem. 2009 Sep 4;284(36):24644-52. DOI: 10.1074/jbc.M109.03439710.1074/jbc.M109.034397278205319581301